This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

'Fast Money' Recap: Looking for High-Growth Investment Opportunities

Tim Seymour, managing partner of Triogem Asset Management, said investors have been "poorly positioned" with the expectation that yields were going to increase in 2014 so far. However, he argued that the U.S. economy is doing pretty good and that yields will eventually head higher because of this, not lower. 

Time (TIME) is reportedly in advanced talks to acquire a stake in Vice Media, which would value Vice at roughly $2.2 billion. Dan Nathan, co-founder and editor of, said the valuation of Vice is likely to continue moving higher after this deal because it has successfully built a "great business model."

Sony (SNE) announced its Playstation TV on Wednesday. Seymour said that it's exciting news, although the technology has been around for a while and it will pit Sony against Microsoft (MSFT). He added that Sony may struggle after the next six to nine months but seems to have a bottom near $16. 

Las Vegas Sands (LVS) was downgraded by UBS to hold from buy. Kelly said the slowing revenue from Macau will likely weigh on the company's results. It's "going to be challenged for a while," he added. 

Nathan pointed out that 75% of Wynn Resorts' (WYNN) profits come from Macau, and a slowdown in the region will certainly hurt the company.  He "wouldn't touch it." 

CNBC's Meg Tirrell was a guest on the show to discuss some up-and-coming products and companies in the health care technology space. Covidien (COV) bought Given Imaging for $860 million 2013. The company now has a device that allows patients to ingest a "camera pill" that takes photos of the digestive tract. It could perhaps eliminate the colonoscopy. 

Other companies, such as Sanofi (SNY) and Illumina  (ILMN) are creating mobile applications that can benefit both patients and doctors. GlaxoSmithKline (GSK) is also working on what it called Electroceuticals, which is where rice-sized electrical devices attach to patients' nerves. The treatment may help treat diabetes, obesity and hypertension but is likely 10 years away from becoming reality. 

Adami said Covidien is not an earnings or valuation play, it's an investment in the future. It still make sense to own despite the recent run-up in the share price, he urged. 

Nathan liked shares of GlaxoSmithKline, which are 5% from the all-time highs. Technically, the stock looks great, he said, along with a solid dividend yield of 4.8%. 

2 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs